Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update 2024-11-01 19:00
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update 2024-07-26 19:00
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer 2024-07-15 19:00
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases 2024-05-28 19:00
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease 2024-05-03 19:00
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update 2024-04-30 19:00
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update 2024-03-21 19:00
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum 2023-12-20 20:00
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors 2023-12-11 20:00
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update 2023-10-26 19:00
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 2023-10-12 19:00
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update 2023-07-27 19:00
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease 2023-06-12 19:00
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease 2023-05-25 19:00
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease 2023-05-19 19:00
HanAll Biopharma Reports First Quarter Results and Provides Business Update 2023-04-28 19:00
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth 2023-03-29 19:00
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program 2023-03-15 19:00
HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis 2023-03-06 20:00
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities 2023-02-10 20:00
1 2